STOCK TITAN

ClearOne (CLRO) S-1 Filings

CLRO NASDAQ

Here are the S-1 registration statements from ClearOne, Inc. (CLRO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-1 covers the registration statement a company files to sell shares publicly, so if you follow CLRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLRO filings page.

Rhea-AI Summary

ClearOne, Inc. (CLRO) has filed an amended Form S-1 for a mixed offering, registering a best-efforts primary sale of between 2,857,143 and 4,285,714 Units at $3.50 per Unit, plus the potential resale by selling stockholders of up to 2,496,162 shares of common stock. Each Unit includes one share of common stock and a warrant to buy one share at $10.00, exercisable immediately and expiring six months after issuance.

The primary raise targets $10–$15 million in gross proceeds, with estimated net proceeds of about $13.75 million at the maximum, to repay a loan to First Finance Ltd., fund Cortigent’s Orion and Stroke Recovery System development and pivotal trials, manufacture devices, and cover working capital and Merger expenses. The issuance could exceed 20% of current voting power, so stockholders approved it under Nasdaq Listing Rule 5635(d) on August 25, 2026.

ClearOne’s business now mainly maintains its listing while pursuing a Merger under which Cortigent, a pre-revenue neurostimulation developer with Breakthrough Device designation for its Orion visual prosthesis, would become a wholly owned subsidiary. Cortigent has significant accumulated losses, a going-concern warning, and plans long, capital-intensive clinical programs, so the combined company’s outlook depends heavily on successful financing, including this offering, and eventual FDA approvals and reimbursement.

Rhea-AI Summary

ClearOne, Inc. plans a mixed primary and resale securities transaction and a transformative merger. The company is offering on a best-efforts basis a minimum of 2,857,142 and a maximum of 4,285,714 Units at $3.50 per Unit, each Unit consisting of one share of common stock and a six‑month Warrant exercisable at $10.00 per share. The primary offering targets gross proceeds between $10.0 million and $15.0 million, with estimated net proceeds of about $13.75 million if the maximum is sold, and concurrently registers up to 2,496,162 existing shares for resale by selling stockholders. Common shares outstanding would be 5,532,554 at the minimum and 6,961,126 at the maximum, excluding Warrant exercises. Proceeds are expected to fund repayment of a loan to First Finance Ltd., development and pivotal trials of Cortigent’s Orion and Stroke Recovery Systems, device manufacturing, general working capital and expenses related to a planned merger whereby Cortigent will become a wholly owned subsidiary. Both ClearOne and Cortigent disclose recurring losses, limited cash and substantial doubt about their ability to continue as going concerns, and highlight significant clinical, regulatory, financing and Nasdaq listing risks.